We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.60 | 1.31% | 277.54 | 277.85 | 279.10 | 279.84 | 273.3811 | 274.18 | 2,323,167 | 00:45:10 |
From May 2022 to May 2024
By Jeffrey T. Lewis
Amgen Inc.'s profit increased in the third quarter, helped by lower operating expenses.
The Thousand Oaks, Calif.-based biotech company reported net income of $2.14 billion in the three months through September, compared with $1.88 billion in the same period a year earlier. Earnings per share reached $3.98 from $3.31 and adjusted earnings per share rose to $4.70 from $4.08. Revenue declined to $6.65 billion from $6.71 billion in the year-earlier period.
The sales figure outperformed market expectations, while the profit figure fell short. The consensus compiled by FactSet was for sales of $6.56 billion and net income of $2.38 billion.
The company's total operating expenses fell to $3.99 billion from $4.33 billion , partly because of a $400 million licensing related payment Amgen made in the third quarter of last year that wasn't repeated this year.
Write to Jeffrey T. Lewis at jeffrey.lewis@wsj.com
(END) Dow Jones Newswires
November 03, 2022 16:43 ET (20:43 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
